M&

Merck & Co.(MRK)

RAHWAY, NJ
Pharmaceutical4 H-1B visas (FY2023)
OncologyVaccinesInfectious DiseaseCardiovascularImmunology
Funding Stage
PUBLIC
Employees
69,000
Open Jobs
672

Products & Portfolio (11)

39 discontinued products not shown

ASMANEX HFA
mometasone furoate
Peak
INHALATION · AEROSOL, METERED
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor, which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.
asthma
2014
30
ASMANEX TWISTHALER
mometasone furoate
LOE Approaching
INHALATION · POWDER
anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of inhibitory effects on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, and lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines) involved in inflammation and in the asthmatic response. These anti-inflammatory actions of corticosteroids may contribute to their efficacy in asthma. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor, which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown. Though effective for the treatment of asthma, corticosteroids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When corticosteroids are discontinued, asthma stability may persist for several days or longer.
children less than 4 years of ageasthma
2005
30
BELSOMRA
suvorexant
Peak
ORAL · TABLET
Orexin Receptor Antagonists
insomnia characterized by difficulties with sleep onset and/or sleep maintenanceinsomniacharacterized by difficulties with sleep onset and/or sleep maintenance ()
2014
0
BRIDION
sugammadex
LOE Approaching
INTRAVENOUS · SOLUTION
cyclodextrin. It forms a complex with the neuromuscular blocking agents rocuronium and vecuronium, and it reduces the amount of neuromuscular blocking agent available to bind to nicotinic cholinergic receptors in the neuromuscular junction. This results in the reversal of neuromuscular blockade induced by rocuronium and vecuronium.
2015
15
CELESTONE SOLUSPAN
betamethasone acetate and betamethasone sodium phosphate
LOE Approaching
INJECTION · INJECTABLE
CLINICAL PHARMACOLOGY Glucocorticoids, naturally occurring and synthetic, are adrenocortical steroids that are readily absorbed from the gastrointestinal tract. Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their anti-inflammatory effects in disorders of many organ systems. A derivative of prednisolone, betamethasone has a 16β-methyl group that enhances the anti-inflammatory action of the molecule and reduces the sodium- and water-retaining properties of the fluorine atom bound at carbon 9. Betamethasone sodium phosphate, a soluble ester, provides prompt activity, while betamethasone acetate is only slightly soluble and affords sustained activity.
dermatomyositispolymyositissystemic lupus erythematosus+16 more
1965
30
CLARINEX
desloratadine
LOE Approaching
Oral · Tablet
1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor-binding study in guinea pigs showed that desloratadine does not readily cross the blood brain barrier. The clinical significance of this finding is unknown. Pseudoephedrine sulfate is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine sulfate is recognized as an effective agent for the relief of nasal congestion due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.
2002
30
CLARINEX
desloratadine
LOE Approaching
Oral · Tablet
1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor-binding study in guinea pigs showed that desloratadine does not readily cross the blood brain barrier. The clinical significance of this finding is unknown. Pseudoephedrine sulfate is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine sulfate is recognized as an effective agent for the relief of nasal congestion due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.
2002
30
CLARINEX
desloratadine
LOE Approaching
ORAL · TABLET
Histamine H1 Receptor Antagonists
2001
30
CLARINEX
desloratadine
LOE Approaching
ORAL · SYRUP
1 -receptor histamine antagonist activity. Receptor binding data indicate that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor-binding study in guinea pigs showed that desloratadine does not readily cross the blood brain barrier. The clinical significance of this finding is unknown. Pseudoephedrine sulfate is an orally active sympathomimetic amine and exerts a decongestant action on the nasal mucosa. Pseudoephedrine sulfate is recognized as an effective agent for the relief of nasal congestion due to allergic rhinitis. Pseudoephedrine produces peripheral effects similar to those of ephedrine and central effects similar to, but less intense than, amphetamines. It has the potential for excitatory side effects.
2004
30
CLARINEX-D 12 HOUR
desloratadine and pseudoephedrine sulfate
LOE Approaching
ORAL · TABLET, EXTENDED RELEASE
Histamine H1 Receptor Antagonists
2006
30
COZAAR
losartan potassium
LOE Approaching
ORAL · TABLET
[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT 2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Neither losartan nor its principal active metabolite exhibits any partial agonist activity at the AT 1 receptor, and both have much greater affinity (about 1000-fold) for the AT 1 receptor than for the AT 2 receptor. In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT 1 receptor. The active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, non-competitive inhibitor of the AT 1 receptor. Neither losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin), nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
hypertension in adultsolderto lower blood pressure+8 more
1995
30

Pipeline & Clinical Trials

Sitagliptin
Type 1 Diabetes
N/A
Clinical Trials (5)
NCT01131182Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)
Phase 4
NCT00833027ALPHA Sitagliptin Add on to Metformin (0431-103)
Phase 4
NCT01859793Effects of Sitagliptin on Endothelial Function in Type 2 Diabetes on Background Metformin Therapy
Phase 4

+2 more

A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS
Diabetes
N/A
Clinical Trials (1)
NCT01998269A Mixed Methods Approach to the Development and Testing of the Measure of Drug Self-Management (MeDS)
N/A
Long- and intermediate- acting insulins
Diabetes
N/A
Real time PCR
CMV
N/A
Clinical Trials (1)
NCT04280380Cytomegalovirus Infection in Critically Ill Patients and Patients Receiving Anticancer Therapy
N/A
Functional Living Index - Emesis
Vomiting
N/A
Clinical Trials (1)
NCT00696280Observational Study of Delayed Nausea and Vomiting
N/A
non-interventional
Antiemetic Therapy
N/A
Clinical Trials (4)
NCT00911222Epidemiological EMESIS-Registry
N/A
NCT01125475A Scandinavian Non-interventional Study of Adherence to RebiSmart Administered Rebif New Formulation (RNF) Treatment in Relapsing Remitting Multiple Sclerosis (RRMS) Subjects
N/A
NCT07456436Data-Driven Strategies for Patient Engagement About Cancer Clinical Trials
N/A

+1 more

Exposure to methylprednisolone during pregnancy
Multiple Sclerosis
N/A
Clinical Trials (1)
NCT04832269Effects of a Multiple Sclerosis Relapse Therapy on Offspring Neurocognitive Development and Behaviour
N/A
Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-11
Type 2 Diabetes
N/A
Clinical Trials (1)
NCT01472341Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
N/A
Clinical Trials (5)
NCT05435209Effectiveness of the Q-HPV Vaccine 9-years Post Vaccination Among HIV Positive Adolescents
Phase 4
NCT01101750Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls?
Phase 4
NCT05557370Immunogenicity of HPV Vaccine in Transplant Recipients.
Phase 4

+2 more

Clinical Trials (1)
NCT04672772Cetuximab Plus Paclitaxel as First Line for Recurrent and/or Metastatic SCCHN: Real World Data.
N/A
Vitamin D and Physical Function in Older Adults
Vitamin D
N/A
Clinical Trials (1)
NCT00710957Vitamin D and Physical Function in Older Adults
N/A
Disease Management Assessment
Chemotherapy Induced Nausea and Vomiting
N/A
Clinical Trials (5)
NCT00211601Study of Chemotherapy and Patient Health Outcomes for Nausea and Emesis (0000-041)
N/A
NCT00211575Instrument Utility for Suspected Asthma (0000-042)(COMPLETED)
N/A
NCT00145080Comparison of Osteoporosis Disease Management Strategies (0000-039)
N/A

+2 more

Post Pandemic Pneumococcal Carriage Among Children and Adults
Pneumococcal Carriage
N/A
Clinical Trials (1)
NCT06373328Post Pandemic Pneumococcal Carriage Among Children and Adults
N/A
Hanyang University Medical Center Arthritis Network
Arthritis, Rheumatoid
N/A
Individualized Feedback
HIV Prevention
N/A
Clinical Trials (1)
NCT05165745Stick2PrEP Cisgender Women and Trans Individuals
N/A
Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.
Hip Fracture
N/A
Clinical Trials (1)
NCT00414830Systematic Prevention of Further Fractures in Patients With Hip Fractures and Osteoporosis.
N/A
There are no interventions in this study. All participants complete online surveys.
Lung Cancer Patients
N/A
A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in th
Infertility
N/A
Clinical Trials (1)
NCT01112618A Non-interventional Study to Identify the Patients With Severe Luteinizing Hormone Deficiency in the Daily Practice
N/A
Previously admitted COVID-19 patients in intensive care units
COVID-19
N/A
Clinical Trials (1)
NCT05256316Risks of Bacterial and Fungal Superinfection in Patients With COVID-19
N/A
Clinical Trials (1)
NCT02218320Comparison of Virologic and Immunologic Responses to Raltegravir and Dolutegravir in the Gastrointestinal Tract of HIV-Positive Adults
N/A
Temozolomide
Glioblastoma
N/A
Clinical Trials (1)
NCT00725010Temozolomide in Concomitant Radiochemotherapy Followed by Sequential Temozolomide Chemotherapy - Observational Program (Study P04816)
N/A
Isentress Re-examination Study (MK-0518-115)
HIV Infection
N/A
Clinical Trials (1)
NCT01042808Isentress Re-examination Study (MK-0518-115)
N/A
Clinical Trials (5)
NCT00939952Ertapenem Pharmacokinetics in Patients in Continuous Ambulatory Peritoneal Dialysis
Phase 4
NCT00157898A Study to Evaluate Ertapenem Versus It's Comparator in the Treatment of Complicated Intra-abdominal Infections in Adults (0826-050)(COMPLETED)
Phase 4
NCT01159379Safety of Ertapenem in Beta-lactam Allergic Patients.
Phase 4

+2 more

Pain Quality Study
Low Back Pain
N/A
Clinical Trials (1)
NCT01321190Pain Quality Study
N/A
Indinavir sulfate
HIV Infections
N/A
Clinical Trials (5)
NCT00002179The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection
Phase 4
NCT00002386Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
Phase 4
NCT00002376The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients
Phase 4

+2 more

Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
ANCA Associated Vasculitis
N/A
Clinical Trials (1)
NCT04916704Subclinical Cytomegalovirus Reactivation in Acute ANCA-associated Vasculitis
N/A
Follitropin Beta;MSD
Infertility
N/A
Clinical Trials (1)
NCT03300518Effectiveness of Estradiol Valerate Pretreatment in Antagonist Protocol for Poor Ovarian Response Patient
N/A
A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenotypes of Knee Osteoarth
Knee Osteoarthritis
N/A
Clinical Trials (1)
NCT03883568A 2-year, European Multicentre Study to Describe, Validate, and Predict Phenotypes of Knee Osteoarthritis
N/A
Clinical Trials (4)
NCT05722652A Multicomponent Clinic-based Intervention to Promote COVID-19 Vaccine Intention and Uptake Among Diverse Youth and Adolescents
N/A
NCT05891626Group Intervention on Vaccine Confidence
N/A
NCT06374134The Impact of Community and Patient Engagement Practices on Vaccine Confidence in the United States
N/A

+1 more

N/A
Clinical Trials (5)
NCT01291394To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in France
N/A
NCT01555528To Assess the Level of Adherence of Subjects Receiving SAIZEN® Via Easypod™ in Mexico
N/A
NCT00738205Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector
N/A

+2 more

A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
HIV
N/A
Clinical Trials (1)
NCT02597790A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects
N/A
Imaging evaluation for vascular assessment
Myocardial Infarction
N/A
Clinical Trials (1)
NCT04058782Impact of Peripheral Vascular Stiffness Assessment on Risk Prediction in Patients With Myocardial Infarction
N/A
Raltegravir
HIV
N/A
Clinical Trials (1)
NCT01042652A Trial to Compare Raltegravir Versus Nevirapine as Anchor Drug for HIV+ Chinese IDUs on Methadone Maintenance
N/A
Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Reg
Human Immunodeficiency Virus
N/A
Clinical Trials (1)
NCT01814722Quality of Life of HIV-infected Participants Switched to Raltegravir Versus Other Antiretroviral Regimens (MK-0518-266)
N/A
Daptomycin 6mg/kg/day
Fasciitis, Necrotizing
N/A
Clinical Trials (1)
NCT00261807Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections
N/A
Peginterferon alfa-2b
Hepatitis C, Chronic
N/A
Clinical Trials (5)
NCT00202839Peg-Intron/Ribavirin in G 1 HCV for Non-Extended Versus 24 Week Extended Treatment After 24 Weeks (Study P04144)(COMPLETED)
Phase 4
NCT00255008Peg-Intron and Rebetol Therapy in Treatment of Naive Hepatitis C Patients: A Comparison of Race and Genotype on Treatment Outcome (Study P04212)
Phase 4
NCT00687544Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C in HIV-Infected Subjects (Study P04469)(TERMINATED)
Phase 4

+2 more

Comprehensive non invasive cardiovascular examination
Coronary Heart Disease
N/A
Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
Low CETP Activity
N/A
Clinical Trials (1)
NCT01916512Relationship Between CETP Deficiency and Atherosclerosis in Patients With Hyperalphalipoproteinemia
N/A
Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
Alzheimer's Disease
N/A
Clinical Trials (1)
NCT01730430Cerebrospinal Fluid (CSF) Biomarkers Alzheimer's Disease (AD) and Non-AD Dementias
N/A
Endomicroscopy in IBD Patients
Crohn's Disease
N/A
Clinical Trials (1)
NCT01417728Endomicroscopy in IBD Patients
N/A
Clinical Trials (1)
NCT00908011Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
N/A
gonadotropins plus GnRH antagonists
INFERTILITY
N/A
Clinical Trials (1)
NCT01645241Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation
N/A
Clinical Trials (1)
NCT00727077Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)
N/A
The Hyfrecator ® 2000 Electrosurgical System
Anal Dysplasia
N/A
Clinical Trials (1)
NCT02503111The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With Men
N/A
Aprepitant
Lymphoma
N/A
Clinical Trials (1)
NCT00651755Aprepitant's Effect on Drug Metabolism in Multi-Day Combination (CHOP/R-CHOP) Chemotherapy Regimen in Lymphoma Patients
N/A
Pegylated Liposomal Doxorubicin
Breast Neoplasm
N/A
Clinical Trials (1)
NCT00736333A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
N/A
Cancer care delivery
Care Delivery
N/A
Clinical Trials (1)
NCT06652347Understanding the Preferences and Views of Older Adults on the Use of Geriatric and Objective Functional Assessments for Cancer Treatment Planning.
N/A
Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
Chronic Hepatitis C Infection
N/A
Clinical Trials (1)
NCT02065999Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients
N/A
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
N/A
Clinical Trials (1)
NCT04997148Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
N/A
dyspnea grade ≥ II according NYHA-WHO
CTEPH
N/A
Clinical Trials (1)
NCT03953560Symptom-related Screening for Early Detection of CTEPH.
N/A

Open Jobs (672)

Associate Director, External Manufacturing

IND - Maharashtra - Mumbai (WeWork)
Yesterday

Senior Specialist, SAP SD Billing & AR plus Online Payments

IND - Telangana - Hyderabad (HITEC City)
2d ago

Pharmaceutical Information Specialist, Onco

CHN - Yunnan - Kunming
2d ago

Assoc. Spclst, Qual. Sys. & Compliance (WDA)

SGP - Singapore - Singapore (50 Tuas West Dr)
2d ago

Associate Director, Marketing Comms/Channels

USA - Pennsylvania - North Wales (Upper Gwynedd)
3d ago
$142K - $224K/yr

Senior Specialist - SAP Integration Architect

USA - New Jersey - Rahway
4d ago
$117K - $184K/yr

Senior Specialist , Data Science, Ophthalmology & Technology

USA - Pennsylvania - North Wales (Upper Gwynedd)
4d ago
$129K - $203K/yr

Senior Specialist, Cybersecurity Engineering

USA - New Jersey - Rahway
4d ago
$117K - $184K/yr

Dir. , Technical Product Management

USA - New Jersey - Rahway
4d ago
$170K - $267K/yr

Agent(e) de liaison médicale et scientifique, Oncologie (Québec)/ Medical and Scientific Liaison (MSL), Oncology (Québec)

CAN - Quebec - Kirkland (16750 Transcanada)
4d ago

Intern - DIMQ (Distribution In-Market Quality)

SGP - Singapore - Singapore (MYP Centre WeWork)
4d ago

Associate Director, Business Insights & Analytics, Ophthalmology & Technology

USA - Pennsylvania - North Wales (Upper Gwynedd)
4d ago
$157K - $247K/yr

EU HTA Dossier Lead (m/f/d)

CHE - Zurich - Zurich (The Circle)
4d ago

Associate Director, Business Insights & Analytics, Immunology

USA - Pennsylvania - North Wales (Upper Gwynedd)
4d ago
$157K - $247K/yr

Hospital / Institutional Customer Representative - IOWA, IA

USA - Iowa - Des Moines
4d ago
$106K - $167K/yr

Sr. Specialist, Engineering (Onsite)

USA - New Jersey - Rahway
4d ago
$117K - $184K/yr

Executive Director, Ophthalmology Scientific and Life Cycle Management Strategy

USA - New Jersey - Rahway
4d ago
$256K - $403K/yr

Jefe de Eléctrica e Instrumentación

URY - Montevideo - Montevideo (Prondil)
4d ago

National Account Director, Payer/PBM Segment

USA - Pennsylvania - North Wales (Upper Gwynedd)
4d ago
$191K - $300K/yr

Associate Director, Engineering - Tech Transfer Lead

USA - North Carolina - Wilson
4d ago
$129K - $203K/yr

Senior Specialist, Engineering (Onsite)

USA - New Jersey - Rahway
4d ago
$117K - $184K/yr

Distinguished Scientist, Neglected Tropical Disease Discovery

USA - Pennsylvania - West Point
4d ago
$232K - $365K/yr

Senior Director (Senior Principal Scientist), Translational Medicine, Immunology

USA - Massachusetts - Boston (MA Parcel B Laboratory)
4d ago
$287K - $452K/yr

Senior Specialist, Customer Account Representative

USA - Pennsylvania - North Wales (Upper Gwynedd)
4d ago
$117K - $184K/yr

Specialist, Business Consulting

USA - North Carolina - Wilson
4d ago
$79K - $125K/yr
View all 672 open positions →
Interview Prep Quick Facts
Portfolio: 309 approved products, 178 clinical trials
Top TAs: Oncology, Infectious Diseases, Metabolic Diseases
H-1B (2023): 4 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 672 active jobs
Portfolio Health
Pre-Launch35 (11%)
Launch2 (1%)
Growth1 (0%)
Peak26 (8%)
LOE Approaching218 (71%)
Post-LOE27 (9%)
309 total products
Therapeutic Area Focus
Oncology
6 marketed1587 pipeline
Infectious Diseases
21 marketed604 pipeline
Metabolic Diseases
6 marketed329 pipeline
Neurology
13 marketed207 pipeline
Cardiovascular
15 marketed161 pipeline
Immunology
18 marketed124 pipeline
Respiratory
18 marketed123 pipeline
Nephrology
3 marketed81 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$60.1B1%
R&D Spend
$30.5B(51%)125%
Net Income
$365M
Cash
$13.2B

Hiring Trend

Actively Hiring
672
Open Roles
+677
Added
-5
Filled/Removed

Based on last 2 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
4
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub